Sundari Mase

ORCID: 0000-0001-5363-0637
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Tuberculosis Research and Epidemiology
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Infectious Diseases and Tuberculosis
  • Pneumonia and Respiratory Infections
  • Diagnosis and treatment of tuberculosis
  • Mycobacterium research and diagnosis
  • Pharmaceutical studies and practices
  • SARS-CoV-2 and COVID-19 Research
  • Viral gastroenteritis research and epidemiology
  • Antibiotics Pharmacokinetics and Efficacy
  • Biosimilars and Bioanalytical Methods
  • Chronic Disease Management Strategies
  • Plant-based Medicinal Research
  • Animal Virus Infections Studies
  • Pharmaceutical Economics and Policy
  • COVID-19 epidemiological studies
  • Cancer therapeutics and mechanisms
  • Bacillus and Francisella bacterial research
  • COVID-19 and healthcare impacts
  • Infection Control and Ventilation
  • Poxvirus research and outbreaks
  • HIV/AIDS drug development and treatment
  • Healthcare Systems and Reforms
  • Botulinum Toxin and Related Neurological Disorders
  • Healthcare cost, quality, practices

Centers for Disease Control and Prevention
2010-2024

National Center for Emerging and Zoonotic Infectious Diseases
2024

Sonoma County Library
2020-2021

World Health Organization Regional Office for South-East Asia
2018-2020

California Retina Consultants
2020

Film Independent
2020

National Center for HIV/AIDS Viral Hepatitis STD and TB Prevention
2015-2019

Infectious Diseases Society of America
2019

European Respiratory Society
2019

World Health Organization - India
2018-2019

Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionGood Practices for Treati...Treatment MDR-TB, Numb...Drugs and Drug ClassesBuilding a Treatment Regi...Role Therapeutic ...Shorter-Course, Standardi...Role Surgery in MDR-TBTreatment Isoniazid-Re...Treatment MDR-TB Sp...Treatment Contacts Exp...Summary Key Difference...ReferencesCITING ARTICLES

10.1164/rccm.201909-1874st article EN American Journal of Respiratory and Critical Care Medicine 2019-11-15

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome 2 (SARS-CoV-2) has spread globally, with >365,000 cases in California as of 17 July 2020. We investigated the genomic epidemiology SARS-CoV-2 Northern from late January to mid-March 2020, using samples 36 patients spanning nine counties and Grand Princess cruise ship. Phylogenetic analyses revealed cryptic introduction at least seven different lineages into California, including epidemic WA1 strains...

10.1126/science.abb9263 article EN cc-by Science 2020-06-08

Linezolid is a new antibiotic with activity against Mycobacterium tuberculosis in vitro and animal studies. Several small case series suggest that linezolid poorly tolerated because of the side effects anemia/thrombocytopenia peripheral neuropathy. To characterize our clinical experience linezolid, California Department Public Health Tuberculosis Control Branch's Multidrug-Resistant (MDR-TB) Service reviewed cases which MDR-TB treatment regimens included therapy.Record review was performed...

10.1086/648675 article EN Clinical Infectious Diseases 2009-11-30

Abstract To describe factors associated with multidrug-resistant (MDR), including extensively-drug-resistant (XDR), tuberculosis (TB) in the United States, we abstracted inpatient, laboratory, and public health clinic records of a sample MDR TB patients reported to Centers for Disease Control Prevention from California, New York City, Texas during 2005–2007. At initial diagnosis, was detected 94% 130 XDR 80% 5 patients. Mutually exclusive resistance 4% XDR, 17% pre-XDR, 24% total first-line...

10.3201/eid2005.131037 article EN cc-by Emerging infectious diseases 2014-03-20

Few studies have shown the operational feasibility, safety, tolerability, or outcomes of multidrug-resistant latent tuberculous infection (MDR LTBI) treatment. After two simultaneous tuberculosis (MDR-TB) outbreaks in Chuuk, Federated States Micronesia, infected contacts were offered a 12-month fluoroquinolone (FQ) based MDR LTBI treatment regimen.Between January 2009 and February 2012, 119 MDR-TB patients followed using prospective observational study design. disease was excluded, 12 months...

10.5588/ijtld.13.0028 article EN The International Journal of Tuberculosis and Lung Disease 2014-07-11

Randomized controlled trials have demonstrated that the newest latent tuberculosis (LTBI) regimen, 12 weekly doses of directly observed isoniazid and rifapentine (3HP), is as efficacious 9 months isoniazid, with a greater completion rate (82% vs 69%); however, 3HP has not been assessed in routine healthcare settings. Observational cohort LTBI patients receiving through 16 US programs was used to assess treatment completion, adverse drug reactions, factors associated discontinuation. Of 3288...

10.1093/cid/cix505 article EN public-domain Clinical Infectious Diseases 2017-05-26

In 2012, the Food and Drug Administration approved use of bedaquiline fumarate as part combination therapy for multidrug-resistant tuberculosis (MDR TB). We describe treatment outcomes, safety, tolerability in our case series.Data on patients started MDR TB between September 2012 August 2016 were collected retrospectively through 4 programs using a standardized abstraction tool. Data analyzed univariate methods. Adverse events graded Common Terminology Criteria Events.Of 14 patients, 7 (50%)...

10.1093/cid/ciz914 article EN public-domain Clinical Infectious Diseases 2019-09-18

Abstract The COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has spread globally, resulting in &gt;300,000 reported cases worldwide as of March 21st, 2020. Here we investigate genetic diversity and genomic epidemiology Northern California using samples from returning travelers, cruise ship passengers, community transmission with unclear infection sources. Virus genomes were sampled 29 patients diagnosed Feb 3rd through Mar 15th. Phylogenetic analyses revealed at least 8...

10.1101/2020.03.27.20044925 preprint EN cc-by-nc-nd medRxiv (Cold Spring Harbor Laboratory) 2020-03-30

Background: In the Federated States of Micronesia and then Republic Marshall Islands (RMI), levofloxacin pharmacokinetics were studied in children receiving directly observed once-daily regimens (10 mg/kg, age >5 years; 15–20 ≤5 years) for either multidrug-resistant tuberculosis disease or latent infection after exposure, to inform future dosing strategies. Methods: Blood samples collected at 0 (RMI only), 1, 2 6 hours (50 children, aged months 15 oral >6 weeks treatment. Clinical...

10.1097/inf.0000000000001022 article EN The Pediatric Infectious Disease Journal 2015-12-10

A population-based study of 135 multidrug-resistant tuberculosis (MDR-TB) patients reported to the Centers for Disease Control and Prevention (CDC) during 2005-2007 found 73% were hospitalized. We analyzed factors associated with hospitalization.We assessed statistically significant multivariable associations US in-patient TB diagnosis, frequency hospitalization, length hospital stay, direct costs health care system.Of 98 hospitalized patients, 83 (85%) foreign-born. Blacks, diabetics, or...

10.5588/ijtld.15.0575 article EN The International Journal of Tuberculosis and Lung Disease 2016-03-09

Abstract Foodborne botulism occurred among inmates at 2 prisons in California 2004 and 2005. In the first outbreak, 4 were hospitalized, of whom required intubation. second event, 1 inmate Pruno, an alcoholic drink made illicitly prisons, was novel vehicle for these cases.

10.3201/eid1501.081024 article EN cc-by Emerging infectious diseases 2008-12-30

To better inform local management of TB-diabetes collaborative activities, we aimed to determine the prevalence diabetes among persons with and without TB association between in Kiribati, a Pacific Island nation.We compared consecutively enrolled cases group randomly selected community controls evidence TB. Diabetes was diagnosed by HbA1c, clinical demographic data were collected. A tuberculin skin test administered controls. The chi-square used assess significance differences We also...

10.1111/tmi.12462 article EN Tropical Medicine & International Health 2015-01-19

The End TB Strategy envisions a world free of tuberculosis-zero deaths, disease and suffering due to tuberculosis by 2035. This requires reducing the global incidence from >1250 cases per million people <100 within next two decades. Expanding testing treatment infection is critical achieving this goal. In high-burden countries, like India, implementation preventive (TPT) remains low priority. analysis article, we explore potential challenges solutions implementing TPT in India. chapter...

10.1136/bmjgh-2018-001135 article EN cc-by-nc BMJ Global Health 2018-10-01

To assess the clinical impact of a molecular beacon (MB) assay that detects multidrug-resistant tuberculosis (MDR TB), we retrospectively reviewed records 127 MDR TB patients with and without MB testing between 2004 2007. Use reduced time to detection treatment TB.

10.1128/jcm.01236-10 article EN Journal of Clinical Microbiology 2010-08-12

Monoresistance to rifamycins necessitates longer and more toxic regimens for tuberculosis (TB). We examined characteristics mortality associated with rifampin-monoresistant (RMR) TB in the United States.We analyzed Mycobacterium culture-positive cases reported National Surveillance System (excluding California) between 1998 2014. defined RMR found on initial drug susceptibility testing possible acquired rifampin-resistant (ARR) TB. assessed temporal trends For both classifications of...

10.1093/cid/ciz491 article EN public-domain Clinical Infectious Diseases 2019-06-07
Coming Soon ...